8-K: CV Sciences Reports Stable Q2 Revenue, Improved Margins, and Strategic Acquisitions

CV Sciences maintained consistent revenue in Q2 2024 while improving gross margins and making strategic acquisitions.

Summary

• CV Sciences reported second quarter 2024 revenue of $4.0 million, consistent with both the second quarter of 2023 and the first quarter of 2024.
• The company's gross margin improved to 47.0% in Q2 2024, up from 43.3% in Q2 2023 and 46.3% in Q1 2024.
• The company's cash balance decreased to $0.5 million at the end of Q2 2024, down from $1.3 million at the end of 2023.
• CV Sciences maintained its position as the top-selling hemp extract brand in the natural product retail channel.
• The company launched new pet chews, which contributed to additional shelf placement and revenue.
• CV Sciences secured $0.9 million in net proceeds through a financing agreement with Streeterville.
• The company reported an adjusted EBITDA loss of $6,000 for Q2 2024, nearing operating cash flow break-even.
• CV Sciences acquired Elevated Softgels, a manufacturer of encapsulated softgels and tinctures.
• Maxim Group LLC was appointed as a financial advisor to explore strategic options including mergers and acquisitions.

Sentiment

Score: 7

Explanation: The document presents a mixed picture with positive improvements in gross margin and EBITDA, but a concerning decrease in cash balance. The strategic acquisition and appointment of a financial advisor are positive signs, but the company still needs to achieve profitability.

Positives

• The company achieved its best gross margin in 13 quarters at 47.0%.
• The adjusted EBITDA loss was minimal at $6,000, showing significant improvement towards break-even.
• The acquisition of Elevated Softgels is expected to provide additional opportunities.
• The appointment of Maxim Group LLC as a financial advisor is expected to accelerate growth.
• B2C sales increased by 4%, driven by subscription revenue.
• The operating loss improved by $0.5 million compared to the same quarter last year.

Negatives

• The cash balance decreased significantly to $0.5 million from $1.3 million at the end of 2023.
• Total units sold decreased by 12.5% in Q2 2024, although this was offset by higher average sales prices.
• The company still reported a net loss of $584,000 for the quarter.

Risks

• The company's cash balance is low, which could limit its ability to fund future growth.
• The company is operating in a challenging environment, which could impact future revenue.
• The company's forward-looking statements are subject to risks and uncertainties, and actual results may differ materially.

Future Outlook

The company plans to grow revenue in the second half of 2024 through recent acquisitions and new product innovations. They also intend to continue to build an efficient and cost-effective consumer products platform and evaluate merger, sale, and acquisition options.

Management Comments

• Joseph Dowling, Chief Executive Officer of CV Sciences, stated that the 47.0% gross margin in the second quarter 2024 is the best in the last 13 quarters.
• Management is pleased with the second quarter 2024 results, noting stable revenues and progress towards profitability.
• The company is excited about the additional opportunities of Elevated Softgels and the appointment of Maxim as a strategic financial advisor.

Industry Context

The company operates in the competitive consumer wellness market, specifically in the hemp extract and nutraceutical space. The company's focus on science-backed products and its position as a top-selling brand in the natural products market are key differentiators. The acquisition of Elevated Softgels is a move to vertically integrate and control more of the supply chain.

Comparison to Industry Standards

• CV Sciences' gross margin of 47% is a positive sign, indicating efficient cost management, however, it is important to compare this to other companies in the nutraceutical and hemp extract space such as Charlotte's Web (CWBHF) or Canopy Growth (CGC) to see how it stacks up against industry averages.
• The company's adjusted EBITDA loss of $6,000 is a significant improvement, but it is still not profitable. Companies like Neptune Wellness Solutions (NEPT) and cbdMD (YCBD) are also working towards profitability in the CBD space, and a comparison of their progress would be useful.
• The acquisition of Elevated Softgels is a strategic move, similar to how other companies in the space are looking to control their supply chain. Comparing the impact of this acquisition to similar moves by competitors would be beneficial.
• The company's B2C sales growth of 4% is a positive sign, but it is important to compare this to the growth rates of other companies in the direct-to-consumer space to see if it is keeping pace with industry trends.

Stakeholder Impact

• Shareholders may be encouraged by the improved gross margin and reduced EBITDA loss, but concerned about the decreased cash balance.
• Employees may be impacted by the company's focus on cost-efficiency and potential strategic changes.
• Customers may benefit from new product innovations and the company's commitment to science-backed products.
• Suppliers may be impacted by the company's acquisition of Elevated Softgels and potential changes in the supply chain.
• Creditors may be concerned about the company's low cash balance and its ability to meet its obligations.

Next Steps

• The company will host a conference call and webcast to discuss the results.
• The company intends to continue to build an efficient and cost-effective consumer products platform.
• The company will continue to evaluate inbound and outbound merger, sale, acquisition or other options.
• The company plans to grow revenue in the second half of 2024 through recent acquisitions and new product innovations.

Key Dates

Keywords

hemp extracts, CBD, nutraceuticals, financial results, gross margin, EBITDA, acquisition, consumer wellness, plant-based foods, strategic advisor